Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hypha LabsFUNI Cash-to-Debt is 0.00 as of Jun. 2026. The stock has 2 warning signs investors should review. Among 208 Medical Diagnostics & Research companies, Hypha Labs ranks worse than 480768.75% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hypha Labs's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.00.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Hypha Labscouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Hypha Labs's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Hypha Labs's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.09.
FUNI's Cash-to-Debt is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.035 * Ranked among companies with meaningful Cash-to-Debt only.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Hypha Labs Cash-to-Debt Related Terms
Hypha Labs Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Hypha Labs's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, Hypha Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypha Labs Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Hypha Labs's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypha Labs (FUNI) has a Cash-to-Debt of 0.00 as of Jun. 2026. According to the industry distribution chart, Hypha Labs ranks #999999 out of 208 companies in the Medical Diagnostics & Research industry.
Is Hypha Labs' Cash-to-Debt too high?
Hypha Labs' current Cash-to-Debt is 0.00. Based on the distribution chart, Hypha Labs ranks #999999 out of 208 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Hypha Labs' Cash-to-Debt compare to IDTA and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, Hypha Labs ranks #999999 out of 208 companies for Cash-to-Debt. This places Hypha Labs in the lower half of its industry. The industry median Cash-to-Debt is 1.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.04, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypha Labs's current Cash-to-Debt is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypha Labs stock overvalued right now?
Hypha Labs (FUNI) has a current Cash-to-Debt of 0.00. The current Cash-to-Debt is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Hypha Labs (FUNI), the current Cash-to-Debt is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FUNI has been successfully added to your 
